

16 September 2022

## Sale of Investment in Omni Innovation

**EVE Health Group (ASX:EVE, EVE or the Company)**, a vertically integrated health, nutrition, and wellness company advises that the shareholders of Omni Innovation, a company in which EVE holds an approximately 38% interest, have entered into a conditional Share Sale Agreement (“Agreement”) with Myopharm Limited, an unlisted Australian biotechnology company.

The Agreement is binding but conditional on Myopharm raising a minimum of \$850,000 by the Completion Date of 15 December 2022. EVE’s portion of the proceeds of the share sale are approximately \$300,000. Omni Innovation shareholders, including EVE, are to receive a distribution of net cash held by Omni Innovation at completion. The funds from the disposal of the investment are in line with the Company’s carrying value of the investment in Omni Innovation as disclosed in the Appendix 4E on 31 August 2022.

*Authorised for release by Bill Fry, Managing Director.*

— ENDS —

***For more information, please contact:***

**Company enquiries**

Bill Fry, Managing Director & CEO  
EVE Health Group Ltd  
+61 8 6465 5500  
[billf@evehealthgroup.com.au](mailto:billf@evehealthgroup.com.au)

**About EVE Health Group**

EVE Health Group, (ASX: EVE) is a leading, vertically integrated producer of branded nutrition, health and wellness products. The Company has global reach and application to fast-growing markets across Australia and New Zealand, Asia Pacific and North America. Our mission is to create high quality, innovative, natural and sustainable health and wellness products that help the wellbeing of consumers and in turn help our people, shareholders and community prosper.

For further information, please visit [www.evehealthgroup.com.au](http://www.evehealthgroup.com.au) and follow us on LinkedIn or Twitter.